• Perpetua Medical posted Q2 net revenue of SEK 5.96 million, more than doubled from a year earlier.
• Operating loss widened to SEK 3.1 million; earnings per share fell to SEK -0.36.
• H1 net sales rose to SEK 10.94 million, up 84.65% year on year; operating loss widened to SEK 5.86 million.
• H1 cash flow turned positive to SEK 12.5 million; cash and cash equivalents totaled SEK 16.83 million.
• CEO Anders Hedlund said positive cash flow requires additional acquisitions; talks continue, with several potential deals possible near term.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perpetua Medical AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 20260821:BIT:0436:0) on August 21, 2026, and is solely responsible for the information contained therein.